Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386700433> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4386700433 endingPage "F2" @default.
- W4386700433 startingPage "F2" @default.
- W4386700433 abstract "ABSTRACT Background Per the guidelines established by the European Society of Cardiology (ESC) guidelines for diagnosing and managing chronic and acute heart failure, Sacubitril/Valsartan, Empagliflozin, and Dapagliflozin are suggested to replace an angiotensin-converting enzyme (ACE) inhibitor to significantly minimize the heart failure (HF) associated risks including hospitalization and possible death of HF ambulatory patients with reduced ejection fraction that remain symptomatic. Objective This work aimed to evaluate the health-related quality of life (HRQOL) changes in HFrEF patients throughout treatment with newly approved medications sacubitril/valsartan, Dapagliflozin, and empagliflozin using Minnesota living with heart failure questionnaire (MLHFQ) and Kansas City Cardiomyopathy Questionnaire (KCCQ) -12 at baseline, 3 months, and 6 months of treatment. Methods This prospective study was conducted on 500 patients with chronic HF with 35% or less LVEF, New York Heart Association class III or IV symptoms who visited Minia university cardiothorasic hospital, cardiology outpatient clinic from period of March 2022 to May 2023. Patients were treated using maximum tolerated doses of guideline-directed medical therapy; angiotensin-converting enzyme inhibitors (ACEIs), ß-blocker (BB), mineralocorticoid receptor antagonist (MRA), and systolic blood pressure greater than 105 mmHg. A total of 3 visits were done (baseline visit, months 3 and 6). At the baseline visit, patients were on ACEIs, BB, MRA, and diuretics and quality of life (QOL) was assessed for this regimen by MLHFQ and KCCQ.12 Then dapagliflozin or empagliflozin was added to the previous regimen, and a reevaluation of patients' QOL was done at 3 months. The ACEI or ARBs was replaced by sacubitril/valsartan, and the reevaluation of QOL was evaluated at 6 months. Results Systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), E/e′ ratio, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were remarkably decreased at 6 months compared to baseline (P value <0.001), at 6 months compared to 3 months (P value <0.001), and at 3 months compared to baseline (P value <0.001). Left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), and potassium were significantly increased at 6 months compared to baseline (P value <0.001), at 6 months compared to 3 months (P value <0.001), and at 3 months compared to baseline (P value <0.001). MLHFQ and KCCQ-23 scores were significantly improved at 6 months compared to baseline (P value <0.001), compared to 3 months (P value <0.001), and at 3 months compared to baseline (P value <0.001). 28 (5.6%) patients had stopped the medications due to adverse events (AEs). Conclusions Treatment of HFrEF patients with sodium-glucose Co-transporter-2 inhibitors (SGLT2i) and/or sacubitril/valsartan is associated with rapid and significant improvement in patients' QOL according to both KCCQ and MLHFQ scores." @default.
- W4386700433 created "2023-09-14" @default.
- W4386700433 creator A5000343725 @default.
- W4386700433 creator A5012002309 @default.
- W4386700433 creator A5042963344 @default.
- W4386700433 creator A5050429018 @default.
- W4386700433 date "2023-09-01" @default.
- W4386700433 modified "2023-10-18" @default.
- W4386700433 title "Effect of Newly Approved Medications Sacubitril/Valsartan, Empagliflozin and Dapagliflozin on the Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction" @default.
- W4386700433 doi "https://doi.org/10.1093/eurheartjsupp/suad113.005" @default.
- W4386700433 hasPublicationYear "2023" @default.
- W4386700433 type Work @default.
- W4386700433 citedByCount "0" @default.
- W4386700433 crossrefType "journal-article" @default.
- W4386700433 hasAuthorship W4386700433A5000343725 @default.
- W4386700433 hasAuthorship W4386700433A5012002309 @default.
- W4386700433 hasAuthorship W4386700433A5042963344 @default.
- W4386700433 hasAuthorship W4386700433A5050429018 @default.
- W4386700433 hasBestOaLocation W43867004331 @default.
- W4386700433 hasConcept C126322002 @default.
- W4386700433 hasConcept C134018914 @default.
- W4386700433 hasConcept C159110408 @default.
- W4386700433 hasConcept C164705383 @default.
- W4386700433 hasConcept C27016395 @default.
- W4386700433 hasConcept C2775887513 @default.
- W4386700433 hasConcept C2775940317 @default.
- W4386700433 hasConcept C2775999527 @default.
- W4386700433 hasConcept C2776754050 @default.
- W4386700433 hasConcept C2777180221 @default.
- W4386700433 hasConcept C2777387769 @default.
- W4386700433 hasConcept C2777422806 @default.
- W4386700433 hasConcept C2778198053 @default.
- W4386700433 hasConcept C2779951463 @default.
- W4386700433 hasConcept C2781413609 @default.
- W4386700433 hasConcept C2910068830 @default.
- W4386700433 hasConcept C555293320 @default.
- W4386700433 hasConcept C71924100 @default.
- W4386700433 hasConcept C78085059 @default.
- W4386700433 hasConcept C84393581 @default.
- W4386700433 hasConceptScore W4386700433C126322002 @default.
- W4386700433 hasConceptScore W4386700433C134018914 @default.
- W4386700433 hasConceptScore W4386700433C159110408 @default.
- W4386700433 hasConceptScore W4386700433C164705383 @default.
- W4386700433 hasConceptScore W4386700433C27016395 @default.
- W4386700433 hasConceptScore W4386700433C2775887513 @default.
- W4386700433 hasConceptScore W4386700433C2775940317 @default.
- W4386700433 hasConceptScore W4386700433C2775999527 @default.
- W4386700433 hasConceptScore W4386700433C2776754050 @default.
- W4386700433 hasConceptScore W4386700433C2777180221 @default.
- W4386700433 hasConceptScore W4386700433C2777387769 @default.
- W4386700433 hasConceptScore W4386700433C2777422806 @default.
- W4386700433 hasConceptScore W4386700433C2778198053 @default.
- W4386700433 hasConceptScore W4386700433C2779951463 @default.
- W4386700433 hasConceptScore W4386700433C2781413609 @default.
- W4386700433 hasConceptScore W4386700433C2910068830 @default.
- W4386700433 hasConceptScore W4386700433C555293320 @default.
- W4386700433 hasConceptScore W4386700433C71924100 @default.
- W4386700433 hasConceptScore W4386700433C78085059 @default.
- W4386700433 hasConceptScore W4386700433C84393581 @default.
- W4386700433 hasIssue "Supplement_F" @default.
- W4386700433 hasLocation W43867004331 @default.
- W4386700433 hasOpenAccess W4386700433 @default.
- W4386700433 hasPrimaryLocation W43867004331 @default.
- W4386700433 hasRelatedWork W2604998822 @default.
- W4386700433 hasRelatedWork W2868803160 @default.
- W4386700433 hasRelatedWork W3134363229 @default.
- W4386700433 hasRelatedWork W3207542847 @default.
- W4386700433 hasRelatedWork W4200158067 @default.
- W4386700433 hasRelatedWork W4210282078 @default.
- W4386700433 hasRelatedWork W4229334242 @default.
- W4386700433 hasRelatedWork W4319600715 @default.
- W4386700433 hasRelatedWork W4353082005 @default.
- W4386700433 hasRelatedWork W4380794495 @default.
- W4386700433 hasVolume "25" @default.
- W4386700433 isParatext "false" @default.
- W4386700433 isRetracted "false" @default.
- W4386700433 workType "article" @default.